Timothy S Chang1, Robert F Lemanske2, David T Mauger3, Anne M Fitzpatrick4, Christine A Sorkness5, Stanley J Szefler6, Ronald E Gangnon1, C David Page1, Daniel J Jackson7. 1. Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, Wis. 2. Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wis; Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wis. 3. Department of Health Evaluation Sciences, Pennsylvania State University, Hershey, Pa. 4. Department of Pediatrics, Emory University School of Medicine, Atlanta, Ga. 5. Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wis. 6. Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, Denver, Colo. 7. Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wis. Electronic address: djj@medicine.wisc.edu.
Abstract
BACKGROUND: Childhood asthma clusters, or subclasses, have been developed by computational methods without evaluation of clinical utility. OBJECTIVE: To replicate and determine whether childhood asthma clusters previously identified computationally in the Severe Asthma Research Program (SARP) are associated with treatment responses in Childhood Asthma Research and Education (CARE) Network clinical trials. METHODS: A cluster assignment model was determined by using SARP participant data. A total of 611 participants 6 to 18 years old from 3 CARE trials were assigned to SARP pediatric clusters. Primary and secondary outcomes were analyzed by cluster in each trial. RESULTS:CARE participants were assigned to SARP clusters with high accuracy. Baseline characteristics were similar between SARP and CARE children of the same cluster. Treatment response in CARE trials was generally similar across clusters. However, with the caveat of a smaller sample size, children in the early-onset/severe-lung function cluster had best response with fluticasone/salmeterol (64% vs 23% 2.5× fluticasone and 13% fluticasone/montelukast in the Best ADd-on Therapy Giving Effective Responses trial; P = .011) and children in the early-onset/comorbidity cluster had the least clinical efficacy to treatments (eg, -0.076% change in FEV1 in the Characterizing Response to Leukotriene Receptor Antagonist and Inhaled Corticosteroid trial). CONCLUSIONS: In this study, we replicated SARP pediatric asthma clusters by using a separate, large clinical trials network. Early-onset/severe-lung function and early-onset/comorbidity clusters were associated with differential and limited response to therapy, respectively. Further prospective study of therapeutic response by cluster could provide new insights into childhood asthma treatment.
RCT Entities:
BACKGROUND: Childhood asthma clusters, or subclasses, have been developed by computational methods without evaluation of clinical utility. OBJECTIVE: To replicate and determine whether childhood asthma clusters previously identified computationally in the Severe Asthma Research Program (SARP) are associated with treatment responses in Childhood Asthma Research and Education (CARE) Network clinical trials. METHODS: A cluster assignment model was determined by using SARP participant data. A total of 611 participants 6 to 18 years old from 3 CARE trials were assigned to SARP pediatric clusters. Primary and secondary outcomes were analyzed by cluster in each trial. RESULTS: CARE participants were assigned to SARP clusters with high accuracy. Baseline characteristics were similar between SARP and CARE children of the same cluster. Treatment response in CARE trials was generally similar across clusters. However, with the caveat of a smaller sample size, children in the early-onset/severe-lung function cluster had best response with fluticasone/salmeterol (64% vs 23% 2.5× fluticasone and 13% fluticasone/montelukast in the Best ADd-on Therapy Giving Effective Responses trial; P = .011) and children in the early-onset/comorbidity cluster had the least clinical efficacy to treatments (eg, -0.076% change in FEV1 in the Characterizing Response to Leukotriene Receptor Antagonist and Inhaled Corticosteroid trial). CONCLUSIONS: In this study, we replicated SARP pediatric asthma clusters by using a separate, large clinical trials network. Early-onset/severe-lung function and early-onset/comorbidity clusters were associated with differential and limited response to therapy, respectively. Further prospective study of therapeutic response by cluster could provide new insights into childhood asthma treatment.
Authors: Mary K Miller; Charles Johnson; Dave P Miller; Yamo Deniz; Eugene R Bleecker; Sally E Wenzel Journal: J Allergy Clin Immunol Date: 2005-10-03 Impact factor: 10.793
Authors: Robert F Lemanske; David T Mauger; Christine A Sorkness; Daniel J Jackson; Susan J Boehmer; Fernando D Martinez; Robert C Strunk; Stanley J Szefler; Robert S Zeiger; Leonard B Bacharier; Ronina A Covar; Theresa W Guilbert; Gary Larsen; Wayne J Morgan; Mark H Moss; Joseph D Spahn; Lynn M Taussig Journal: N Engl J Med Date: 2010-03-02 Impact factor: 91.245
Authors: Stanley J Szefler; Brenda R Phillips; Fernando D Martinez; Vernon M Chinchilli; Robert F Lemanske; Robert C Strunk; Robert S Zeiger; Gary Larsen; Joseph D Spahn; Leonard B Bacharier; Gordon R Bloomberg; Theresa W Guilbert; Gregory Heldt; Wayne J Morgan; Mark H Moss; Christine A Sorkness; Lynn M Taussig Journal: J Allergy Clin Immunol Date: 2005-02 Impact factor: 10.793
Authors: Sumit Gupta; Salman Siddiqui; Pranab Haldar; James J Entwisle; Dean Mawby; Andrew J Wardlaw; Peter Bradding; Ian D Pavord; Ruth H Green; Christopher E Brightling Journal: Thorax Date: 2010-09 Impact factor: 9.139
Authors: Malcolm R Sears; Justina M Greene; Andrew R Willan; Elizabeth M Wiecek; D Robin Taylor; Erin M Flannery; Jan O Cowan; G Peter Herbison; Phil A Silva; Richie Poulton Journal: N Engl J Med Date: 2003-10-09 Impact factor: 91.245
Authors: Joe K Gerald; Lynn B Gerald; Monica M Vasquez; Wayne J Morgan; Susan J Boehmer; Robert F Lemanske; David T Mauger; Robert C Strunk; Stanley J Szefler; Robert S Zeiger; Leonard B Bacharier; Elizabeth Bade; Ronina A Covar; Theresa W Guilbert; Hengameh Heidarian-Raissy; H William Kelly; Jonathan Malka-Rais; Christine A Sorkness; Lynn M Taussig; Vernon M Chinchilli; Fernando D Martinez Journal: J Allergy Clin Immunol Pract Date: 2015-03-14
Authors: Elena Goleva; Denise C Babineau; Michelle A Gill; Leisa P Jackson; Baomei Shao; Zheng Hu; Andrew H Liu; Cynthia M Visness; Christine A Sorkness; Donald Y M Leung; Alkis Togias; William W Busse Journal: J Allergy Clin Immunol Date: 2018-07-27 Impact factor: 10.793
Authors: Edward M Zoratti; Rebecca Z Krouse; Denise C Babineau; Jacqueline A Pongracic; George T O'Connor; Robert A Wood; Gurjit K Khurana Hershey; Carolyn M Kercsmar; Rebecca S Gruchalla; Meyer Kattan; Stephen J Teach; Steven M Sigelman; Peter J Gergen; Alkis Togias; Cynthia M Visness; William W Busse; Andrew H Liu Journal: J Allergy Clin Immunol Date: 2016-10 Impact factor: 10.793
Authors: Rachel S Kelly; Kevin M Mendez; Mengna Huang; Brian D Hobbs; Clary B Clish; Robert Gerszten; Michael H Cho; Craig E Wheelock; Michael J McGeachie; Su H Chu; Juan C Celedón; Scott T Weiss; Jessica Lasky-Su Journal: Am J Respir Crit Care Med Date: 2022-02-01 Impact factor: 21.405